Complications of Giant Cell Arteritis
Giant cell arteritis causes two major categories of complications: disease-related vascular complications (vision loss, stroke, aneurysms, stenoses) and glucocorticoid-related adverse events (diabetes, osteoporosis, fractures, infections, glaucoma), with the latter being nearly universal given that prolonged high-dose glucocorticoid therapy remains the treatment cornerstone.
Disease-Related Complications
Cranial Ischemic Manifestations
GCA directly damages blood vessels, leading to severe cranial complications 1:
- Vision loss: The most devastating complication, ranging from amaurosis fugax to permanent blindness
- Stroke: Results from cranial vessel involvement
- Jaw claudication: Indicates ischemia of masticatory muscles
- Scalp tenderness and headaches: Common presenting symptoms
Large Vessel Complications
Extracranial involvement causes structural vascular damage 1:
- Arterial stenoses: Leading to limb claudication and absent pulses
- Aortic aneurysms: Can progress to dissection
- Arterial occlusions: Causing organ ischemia
Baseline vascular imaging (MR or CT angiography of neck/chest/abdomen/pelvis) should be obtained in all newly diagnosed GCA patients to detect large vessel involvement, with serial monitoring in those with documented involvement to identify aneurysms and stenoses early 1.
Glucocorticoid-Related Complications
High-Frequency Adverse Events
The burden of prolonged glucocorticoid therapy is substantial and dose-dependent 2, 3:
Patients receiving high-dose glucocorticoids (≥30 mg/day prednisone) face dramatically increased risks compared to lower doses (5 mg/day):
- Diabetes: 4.7-fold increased risk 2
- Osteoporosis: 1.9-fold increased risk 2
- Fractures: 2.6-fold increased risk 2
- Glaucoma: 3.5-fold increased risk 2
- Serious infections requiring hospitalization: 3.3-fold increased risk 2
- Death: 2.1-fold increased risk 2
Cumulative Exposure Impact
Real-world data reveals the magnitude of glucocorticoid burden 3, 4:
- Median cumulative dose at 52 weeks: 4,000-4,800 mg prednisone equivalent
- Mean 2-year cumulative dose: 7,600 mg (even in recent cohorts)
- Each 1-gram increase in cumulative glucocorticoid dose increases the odds of any glucocorticoid-related adverse event by 17% in US cohorts and 6% in UK cohorts 3
- Even low-dose maintenance therapy (≤5 mg/day) increases infection risk by 13% and major adverse cardiovascular events by 4% 4
Most Common Glucocorticoid-Related Complications
In descending order of frequency 3:
- Hypertension
- Eye conditions (cataracts, glaucoma)
- Bone health issues (osteoporosis, fractures)
- Glucose intolerance/diabetes
Treatment Duration and Relapse Risk
Prolonged Treatment Requirements
GCA necessitates extended glucocorticoid therapy 5:
- 89.7% of patients remain on glucocorticoids at 1 year
- 75.2% still require glucocorticoids at 2 years
- 44.3% continue glucocorticoids at 5 years
- Mean glucocorticoid dose at year 1: 9.1 mg/day
- Mean glucocorticoid dose at year 2: 7.8 mg/day
Relapse Burden
Up to 70% of patients experience disease relapses after glucocorticoid discontinuation or dose reduction, necessitating dose escalation and prolonging cumulative exposure 6, 7.
Clinical Implications and Risk Mitigation
Glucocorticoid-Sparing Strategy
The 2021 ACR/Vasculitis Foundation guidelines strongly recommend glucocorticoids with tocilizumab over glucocorticoids alone for newly diagnosed GCA to reduce cumulative glucocorticoid exposure and associated complications 1. Methotrexate represents an alternative glucocorticoid-sparing option, though with less robust evidence 1.
Common Pitfalls
- Underestimating cumulative glucocorticoid toxicity: Even "low-dose" maintenance therapy (5 mg/day) carries significant risk when continued for years
- Delaying glucocorticoid-sparing agents: Early initiation of tocilizumab or methotrexate reduces total glucocorticoid exposure
- Inadequate monitoring for large vessel complications: Patients with documented large vessel involvement require serial vascular imaging to detect progressive aneurysms or stenoses
- Failing to implement bone protection: All patients on prolonged glucocorticoids warrant osteoporosis prophylaxis
Mortality Impact
Each gram of cumulative glucocorticoid exposure increases mortality risk by 2.4% 4, underscoring the critical importance of minimizing total glucocorticoid burden through early use of steroid-sparing agents and aggressive but safe tapering strategies.